• Kim Brixen, Roland Chapurlat, Angela M Cheung, Tony M Keaveny, Thomas Fuerst, Klaus Engelke, Robert Recker, Bernard Dardzinski, Nadia Verbruggen, Shabana Ather, Elizabeth Rosenberg, and Anne E de Papp.
• Department of Endocrinology, Institute of Clinical Research, University of Southern Denmark, DK-5000 Odense C., Denmark. kbrixen@health.sdu.dk
• J. Clin. Endocrinol. Metab. 2013 Feb 1; 98 (2): 571-80.

ContextOdanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD) in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys.ObjectiveThe objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine.DesignThis was a randomized, double-blind, 2-year trial.SettingThe study was conducted at a private or institutional practice.ParticipantsPARTICIPANTS included 214 postmenopausal women with low areal BMD.InterventionThe intervention included odanacatib 50 mg or placebo weekly.Main Outcome MeasuresChanges in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured.ResultsYear 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P < .001). Bone-resorption marker C-telopeptide of type 1 collagen was significantly lower with odanacatib vs placebo at 6 months and 2 years (P < .001). Bone-formation marker procollagen I N-terminal peptide initially decreased with odanacatib but by 2 years did not differ from placebo. After 6 months, odanacatib-treated women had greater increases in trabecular volumetric BMD and estimated compressive strength at the spine and integral and trabecular volumetric BMD and estimated strength at the hip (P < .001). At the cortical envelope of the femoral neck, bone mineral content, thickness, volume, and cross-sectional area also increased from baseline with odanacatib vs placebo (P < .001 at 24 months). Adverse experiences were similar between groups.ConclusionsOver 2 years, odanacatib decreased bone resorption, maintained bone formation, increased areal and volumetric BMD, and increased estimated bone strength at both the hip and spine.

26 keywords...

hide…